Thoracic Cancer Research Laboratory

项目1：肺癌转化研究。在国际辅助性肺癌试验（IALT）中，研究miRNA对根治性切除的非小细胞肺癌（NSCLC）患者预后的影响以及辅助化疗效果的预测，IALT是一项辅助化疗与随访的随机研究。探讨肺腺癌和肺鳞癌中miRNAs与预后的关系。研究EGFR突变型肿瘤中miR-21表达是否增加。研究miR-34 a、B、c表达水平是否与p53状态相关，以及p53突变肿瘤是否具有降低的miR-34表达。研究let-7是否与野生型K-Ras肿瘤的预后有更强的相关性。该研究已经完成并发表。七种选择的microRNA中没有一种与生存率或与K-RAS或P53突变有显著相关性。项目2：胸腺恶性肿瘤的转化研究。研究胸腺瘤的发病率与匹配的对照组相比，并评估生存模式以及自身免疫性疾病和继发性恶性肿瘤的风险，使用一项全面的基于人群的研究。这项研究已经完成并发表。主要的发现是，年轻患者的预后较差，胸腺瘤的预后比匹配的对照组更差。项目3：胸部恶性肿瘤的临床研究。开发克服EGFR TKI耐药性的靶向药物，特别是第二代EGFR抑制剂、Met抑制剂和HSP-90抑制剂。研究治疗晚期胸腺瘤和胸腺癌的新药。研究肿瘤和活性的替代标志物，以更好地识别可能从靶向药物治疗中获益的患者。项目四：胸腺恶性肿瘤的治疗靶点对晚期胸腺恶性肿瘤患者的石蜡包埋肿瘤和冷冻肿瘤进行CGH和RNA测序以及外显子组测序。识别潜在的基因修饰（扩增、易位、突变等）这可能是相关的预后因素和/或系统治疗的目标。

Project 1: Translational studies in lung cancer. To investigate miRNA influence on prognosis and prediction of effect of adjuvant chemotherapy in radically resected non-small cell lung cancer (NSCLC) in the International Adjuvant Lung Cancer Trial (IALT), a randomized study of adjuvant chemotherapy vs. follow-up. To investigate associations of miRNAs and prognosis in lung adenocarcinoma vs. squamous cell carcinoma. To investigate if miR-21 expression is increased in EGFR mutant tumors. To investigate if miR-34a,b,c expression levels correlate with p53 status and p53 mutant tumors have reduced miR-34 expression. To investigate if let-7 has a stronger association with prognosis in wild-type K-Ras tumors. The study has been completed and published. None of the seven selected microRNAs had a significant correlation with survival or association with K-RAS or P53 mutations. Project 2: Translational studies in thymic malignancies. To study the incidence of thymomas compared to matched controls and also to assess survival patterns as well as risks of autoimmune diseases and secondary malignancies using a comprehensive population-based study. This study has been completed and published. The major findings was that younger patients have a poorer prognosis and that thymomas have a worse prognosis than matched controls. Project 3: Clinical studies in thoracic malignancies. To develop target agents that overcome resistance to EGFR TKIs, in particular, second-generation EGFR inhibitors, Met inhibitors, and HSP-90 inhibitors. Investigate novel agents in patients with advanced thymoma and thymic carcinoma. Study the tumor and surrogate markers of activity, to better identify patients who may benefit from treatment with targeted agents. Project 4: Therapeutic targets in thymic malignancies To perform CGH and RNA sequencing and exome sequencing on paraffin-embedded tumors and frozen tumors from patients with advanced thymic malignancies. To identify potential gene modifications (amplifications, translocations, mutations, etc.) that might be relevant as prognostic factors and or targets for systemic treatment.